CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for NextCell Pharma AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

NextCell Pharma AB
Karolinska Institutet Science Park
Halsovagen 7
Phone: +46 87355595p:+46 87355595 HUDDINGE, 141 57  Sweden Ticker: NXTCLNXTCL
Business Summary
NextCell Pharma AB, formerly Cellaviva AB, is a Sweden-based biopharmaceutical company. The Company is focusing on research and development of stem cell therapies and is also running a tissue establishment and biobank, classified as healthcare provider. NextCell's business concept is to develop and commercialize mesenchymal stem cell products based on the Company's proprietary selection algorithm, primarily for the treatment of autoimmune diabetes, as well as other types of autoimmune diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
11/30/20238/31/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
CEO MathiasSvahn
Medical Director EdvardSmith
Commercial Director LottenLöfberg
3 additional Officers and Directors records available in full report.

Business Names
Business Name
NEXTCL
NXTCL

General Information
Outstanding Shares: 34,379,523 (As of 11/30/2023)
Stock Exchange: STO
Email Address: info@nextcellpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 23, 2024